Induced Proximity Meets Oncology: A New Era In Cancer Therapy | Dr. Angela Coxon, Ph.D., Vice President of Research and Development, Amgen

Send us Fan MailFor more than 30 years, small cell lung cancer has remained one of the most aggressive and difficult-to-treat cancers - marked by rapid progression, high relapse rates, and very few meaningful advances. But that may finally be starting to change.Today, we’re joined by Dr. Angela Coxon, Ph.D., Vice President of Research and Development at Amgen ( https://www.amgen.com/ ), where she helps lead the development of next-generation therapies aimed at tackling exactly these kinds of challenges. Her work spans discovery research, translational medicine, and molecular oncology - bridging the gap between early scientific insight and real-world impact for patients.If you’ve been following the show, you may remember our conversation with Amgen's Dr. Ryan Potts, where we explored the emerging concept of Induced Proximity - the idea that instead of simply blocking biology, we can design drugs that bring components together to create entirely new functions. That idea is now playing out in the clinic through approaches like bispecific T-cell engagers, which physically link immune cells to cancer cells and force a targeted immune response - offering a new way to go after tumors that have historically been very hard to treat.Dr. Coxon earned her D. Phil in Molecular Biology from the University of Oxford and completed postdoctoral training in vascular biology at Harvard Medical School and Brigham and Women’s Hospital. She has built her career at the intersection of cutting-edge biology and strategic drug development, contributing to Amgen’s pipeline in areas of significant unmet need, including lung cancer.#SmallCellLungCancer #SCLC #CancerBreakthrough #Immunotherapy #CancerResearch #Biotech #Amgen #DrugDevelopment #Oncology #CancerTreatment #BiTE #BispecificAntibodies #InducedProximity #PrecisionMedicine #ClinicalTrials #MedicalInnovation #FutureOfMedicine #LungCancerAwareness #TranslationalMedicine #Biology #SciencePodcast #HealthcareInnovation #CancerTherapy #Pharma #NextGenMedicineSupport the show